Showing results (131-140 of 196) with videos related to

Sort By:
Pageof 20
Oncotarget|October 27, 2012
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myelomaNicola Amodio, Marzia Leotta, Dina Bellizzi, et al.
Cancers|September 13, 2025
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern ItalyDaniele Caracciolo, Filippo Antonio Canale, Virginia Naso, et al.
British Journal of Haematology|November 7, 2008
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitorPaola Neri, Pierosandro Tagliaferri, Maria Teresa Di Martino, et al.
Blood|August 19, 2024
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myelomaKatia Grillone, Serena Ascrizzi, Paolo Cremaschi, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|April 2, 2011
Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomesMonica Marra, Giuseppina Salzano, Carlo Leonetti, et al.
Cancer Biology & Therapy|June 14, 2013
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patientsCirino Botta, Vito Barbieri, Domenico Ciliberto, et al.
Cancer Biology & Therapy|August 11, 2010
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patientsPierpaolo Correale, Cinzia Remondo, Salvatore Francesco Carbone, et al.
Haematologica|February 22, 2020
Exploiting MYC-induced PARPness to target genomic instability in multiple myelomaDaniele Caracciolo, Francesca Scionti, Giada Juli, et al.
Oncotarget|November 5, 2017
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)Pierpaolo Pastina, Valerio Nardone, Cirino Botta, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 28, 2024
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experienceNicoletta Staropoli, Francesca Scionti, Valentina Farenza, et al.
Pageof 20